Valeant Pharmaceuticals Intl (Put) (VRX) Shareholder Saba Capital Management LP Increased Its Position by $24.43 Million

April 16, 2018 - By Christine McCrea

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) LogoInvestors sentiment decreased to 0.97 in Q4 2017. Its down 0.02, from 0.99 in 2017Q3. It fall, as 51 investors sold VRX shares while 74 reduced holdings. 54 funds opened positions while 67 raised stakes. 169.66 million shares or 0.12% less from 169.87 million shares in 2017Q3 were reported. Credit Suisse Ag holds 0.02% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 1.32 million shares. 1832 Asset Mngmt LP stated it has 270 shares or 0% of all its holdings. Barclays Public Ltd Co has invested 0.03% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Lpl Financial Ltd Liability Corp has invested 0.01% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Advisory Net Limited Liability reported 0.02% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Twin Tree Mngmt LP reported 4,100 shares. Webster State Bank N A, a Connecticut-based fund reported 300 shares. Canada Pension Plan Invest Board holds 0% or 112,306 shares. Legal And General Group Inc Public Limited Co stated it has 1.61M shares or 0.02% of all its holdings. Comerica Comml Bank has 0% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Dimensional Fund Advsrs LP reported 5.19 million shares stake. Jump Trading Limited Com has invested 0.02% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). 218,123 are owned by Stifel. 1.48 million were accumulated by National Bank Of Nova Scotia. Bnp Paribas Arbitrage Sa has invested 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX).

Since March 8, 2018, it had 3 insider purchases, and 0 selling transactions for $876,370 activity. The insider PAPA JOSEPH C bought $481,500. DE SCHUTTER RICHARD U bought $153,400 worth of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Thursday, March 8.

Boaz Weinstein increased its stake in Valeant Pharmaceuticals Intl (Put) (VRX) by 90.54% based on its latest 2017Q4 regulatory filing with the SEC. Saba Capital Management Lp bought 1.22 million shares as the company’s stock declined 28.77% with the market. The hedge fund run by Boaz Weinstein held 2.57M shares of the health care company at the end of 2017Q4, valued at $53.42M, up from 1.35M at the end of the previous reported quarter. Saba Capital Management Lp who had been investing in Valeant Pharmaceuticals Intl (Put) for a number of months, seems to be bullish on the $5.93B market cap company. The stock decreased 0.96% or $0.165 during the last trading session, reaching $16.985. About 1.17 million shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has risen 42.00% since April 16, 2017 and is uptrending. It has outperformed by 30.45% the S&P500.

Saba Capital Management Lp, which manages about $7.93B and $1.28 billion US Long portfolio, decreased its stake in Wells Fargo Global Dividend (EOD) by 1.28M shares to 1.00 million shares, valued at $5.96M in 2017Q4, according to the filing. It also reduced its holding in Valeant Pharmaceuticals Intl (NYSE:VRX) by 1.24M shares in the quarter, leaving it with 104,759 shares, and cut its stake in Ocean Rig Udw Inc.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Ratings Coverage

Among 14 analysts covering Valeant Pharma (NYSE:VRX), 2 have Buy rating, 4 Sell and 8 Hold. Therefore 14% are positive. Valeant Pharma had 29 analyst reports since October 20, 2017 according to SRatingsIntel. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Underweight” rating given on Thursday, December 14 by JP Morgan. Mizuho maintained the stock with “Sell” rating in Tuesday, November 7 report. Canaccord Genuity maintained the stock with “Hold” rating in Monday, February 26 report. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Hold” rating given on Friday, November 3 by TD Securities. J.P. Morgan downgraded the shares of VRX in report on Thursday, December 14 to “Sell” rating. The rating was maintained by Cantor Fitzgerald on Friday, January 19 with “Buy”. Susquehanna maintained it with “Hold” rating and $17.0 target in Thursday, March 8 report. BMO Capital Markets maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) rating on Monday, October 30. BMO Capital Markets has “Hold” rating and $16.0 target. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Underperform” rating by Mizuho on Friday, December 15. The company was maintained on Wednesday, November 1 by Mizuho.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: